Search

everythinglearnresearchcommunity

for

Search:↓

The user is seeking a quicker-drying carrier for RU58841 and Minoxidil to improve adherence to their hair loss treatment routine. They want to apply it after a morning shower without affecting their hair's appearance.

The post discusses the experiences of individuals with diffuse hair thinning using finasteride, with many reporting no improvement or worsening conditions after 6 months. Various suggestions include persisting with the treatment, checking for underlying conditions, adding minoxidil for volume, adjusting dosage, and considering other potential causes like autoimmune responses and inflammation.

A user is testing clascoterone (Winlevi) on their scalp for hair loss and has noticed a reduction in scalp sebum after one month. They are also using other unspecified treatments and plan to provide an update after the second month.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

PP405, a topical treatment, shows promise for hair growth by activating inactive follicles, with 66% of participants experiencing positive results. The treatment is well-tolerated and may proceed directly to Phase 3 trials, offering a potential alternative to minoxidil and finasteride.

User shows hair loss progress from NW4 to NW2.5 in 2.5 months using RU 8.5-9% daily and topical Dut .1% + RU 5% weekly. Discussion includes managing tension in African American hair and representation of different hair types.

The user experienced hair density loss after increasing finasteride dosage from 3x to 7x a week. It was suggested that this might be a temporary adjustment issue, and adding minoxidil could help.

Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.

The user shared minimal results from using JXL-069 for hair loss, noting a slight lengthening of vellus hairs and plans to switch to a prodrug variant due to limited effectiveness. They also mentioned using finasteride and minoxidil, which have plateaued in results.

The conversation discusses the lack of updates on GT20029 for hair loss treatment, with some users noting recent reports indicating ongoing data collection. There are mentions of other treatments like Pyrilutamide and Minoxidil.

Clascoterone powder is now available, but it's expensive and not widely discussed due to past ineffective results at higher concentrations. Users are skeptical about its effectiveness and are seeking reliable sources.

The user reports visible improvement in hair thickness after using 0.5mg Dutasteride, 2.5mg Minoxidil, and 2% Ketoconazole shampoo, along with supplements, over 3.5 months. Other users note slight improvement and suggest giving it more time.

The conversation is about someone who has not seen hair regrowth after 6 months on finasteride alone, asking if others have experienced delayed results. Some responses indicate that results can sometimes be seen after 12 months, with full effects up to 24 months.

The conversation is about a user's nearly 4-month hair loss treatment regimen, which includes dutasteride every other day, 0.25ml minoxidil on the hairline once a day, and using a 1.5 mm derma stamp every two weeks. Some responses question the need to start multiple treatments simultaneously, while others comment on the visible improvement and the necessity to continue treatment for sustained results.

The user has been using dutasteride for 2 years and minoxidil for 1 year, but their hairline is still receding. Some users think the hairline has maintained or gained density, while others notice minor recession.

The conversation is about whether stemoxydine can shorten the dormant phase after a hair transplant, known as the ugly duckling phase. There is skepticism about whether it actually works as claimed.

User shares 6.5 months of progress using topical finasteride 0.1% and minoxidil 10%, along with lasercomb, dermaroller, Nizoral, scalp massager, and biotin. They seek feedback on their results.

A treatment showed a 20% hair density increase in weeks, with nearly a third of participants experiencing significant results, while questions remain about its long-term efficacy and effectiveness across different scalp areas. There is interest in combining it with finasteride and minoxidil for potentially better outcomes.

The conversation discusses the application frequency of a 1% Koshine solution for hair loss, with recommendations varying between once or twice daily. It is noted that the 1% solution is more effective than the 0.5% solution.

PP405's effectiveness in increasing hair density is questioned due to a small sample size, despite investment from Google Ventures. Users express skepticism and suggest waiting for more conclusive results.

The user experienced significant hair regrowth using a combination of minoxidil, alfatradiol, pyrilutamide, and nizoral, despite previous intolerance to finasteride. They emphasize the importance of consistency in treatment and are optimistic about the results, noting no side effects so far.

Clascoterone, a topical anti-androgen, is generating interest for potentially fewer systemic side effects. Users are curious about its effectiveness and details like concentration and duration of use.

Breezula (cb-03-01) and kx-826 are discussed as hair loss treatments. Kx-826 is available on Kintor's website, while Breezula is available on the grey market.

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.

The conversation discusses Breezula, a hair loss treatment, and its Phase 3 clinical trial recruitment at 50 locations. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

The conversation discusses hair regrowth after one month of using 5% minoxidil, with users noting significant hair growth and varying responses. Some users mention using oral minoxidil and finasteride, with mixed results on hair thickness and growth.

The conversation discusses hair loss treatment progress using Minoxidil, a 0.5mm derma stamp, and caffeine serum, with additional use of rosemary, peppermint, and olive oil. The user is avoiding DHT blockers like Finasteride due to potential interference with other medications.

Reverse conditioning can help achieve volume and well-conditioned hair for those with diffuse thinning. The user also mentioned using dutasteride.

The conversation discusses HMI 115, a new hair loss treatment with promising results, showing a significant increase in hair density after two months. Some users are skeptical, while others are hopeful for its release and potential affordability.

The conversation questions the lack of feedback on the effectiveness of PGE2 and setipiprant for hair loss, despite their availability. The user is puzzled by the absence of reviews or results, whether positive or negative.